Brilinta, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with a history of myocardial infarction (MI) (MI occurred at least one year ago), and a high risk of developing an atherothrombotic event
Dosage/Direction for Use
Brilinta 60 mg twice daily is the recommended dose when an extended treatment is required for patients with a history of MI of at least one year and a high risk of an atherothrombotic event (see “Pharmacology: Pharmacodynamics under Actions”). Treatment may be started without interruption as continuation therapy after the initial one-year treatment with Brilinta 90 mg or other adenosine diphosphate (ADP) receptor inhibitor therapy in ACS patients with a high risk of an atherothrombotic event. Treatment can also be initiated up to 2 years from the MI, or within one year after stopping previous ADP receptor inhibitor treatment. There are limited data on the efficacy and safety of Brilinta beyond 3 years of extended treatment.
*The product images shown are for illustration purposes only and may not be an exact representation of the product.